{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:04:21Z","timestamp":1762207461381,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejim.2025.106516","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:12:41Z","timestamp":1758586361000},"page":"106516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sodium-glucose cotransporter 2 inhibitors may increase iron availability with beneficial effects on erythropoiesis and cardiovascular mortality in patients with type 2 diabetes mellitus. Author\u2019s Reply"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4599-8487","authenticated-orcid":false,"given":"Rossella","family":"Cannarella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Rubulotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Cannarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"La Vignera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6950-335X","authenticated-orcid":false,"given":"Aldo E.","family":"Calogero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.106516_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.106496","article-title":"Sodium-glucose cotransporter 2 inhibitors may increase iron availability with beneficial effects on erythropoiesis and cardiovascular mortality in patients with type 2 diabetes mellitus","author":"Murphy","year":"2025","journal-title":"Eur J Int Med."},{"key":"10.1016\/j.ejim.2025.106516_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2025.06.010","article-title":"A holistic view of SGLT2 inhibitors: from cardio-renal management to cognitive and andrological aspects","volume":"138","author":"Cannarella","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"16","key":"10.1016\/j.ejim.2025.106516_bib0003","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/eurheartj\/ehae917","article-title":"Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial","volume":"46","author":"Angermann","year":"2025","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ejim.2025.106516_bib0004","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1002\/jcp.30851","article-title":"Sodium-glucose co-transporter 2 inhibitors and hematopoiesis","volume":"237","author":"Yaribeygi","year":"2022","journal-title":"J Cell Physiol"},{"issue":"8","key":"10.1016\/j.ejim.2025.106516_bib0005","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ejim.2025.106516_bib0006","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/dom.14517","article-title":"Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: data from a randomized, placebo-controlled study","volume":"23","author":"Thiele","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2025.106516_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175729","article-title":"SGLT2 inhibitor dapagliflozin alleviates intramyocardial hemorrhage and adverse ventricular remodeling via suppressing hepcidin in myocardial ischemia-reperfusion injury","volume":"950","author":"Chen","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.ejim.2025.106516_bib0008","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabet Technol Ther"},{"issue":"7\u20138","key":"10.1016\/j.ejim.2025.106516_bib0009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.mad.2010.04.007","article-title":"The emerging role of iron dyshomeostasis in the mitochondrial decay of aging","volume":"131","author":"Xu","year":"2010","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.ejim.2025.106516_bib0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","article-title":"Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway","volume":"195","author":"Lu","year":"2023","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.106516_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2478\/folmed-2013-0017","article-title":"Effect of testosterone propionate on erythropoiesis after experimental orchiectomy","volume":"55","author":"Delev","year":"2013","journal-title":"Folia Med (Plovdiv)"},{"issue":"7","key":"10.1016\/j.ejim.2025.106516_bib0012","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2337\/dc17-2510","article-title":"Hypogonadotropic hypogonadism in men with diabesity","volume":"41","author":"Dhindsa","year":"2018","journal-title":"Diabet Care"},{"issue":"4","key":"10.1016\/j.ejim.2025.106516_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70064","article-title":"Secondary erythrocytosis among type 2 diabetes mellitus patients with hypogonadism using sodium-glucose cotransporter 2 inhibitors and testosterone replacement therapy","volume":"8","author":"Kabha","year":"2025","journal-title":"Endocrinol Diabet Metab"},{"issue":"10","key":"10.1016\/j.ejim.2025.106516_bib0014","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1007\/s40618-024-02350-1","article-title":"Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy","volume":"47","author":"Gosmanov","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.ejim.2025.106516_bib0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jc.2018-01702","article-title":"Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: a Warning From Two Clinical Cases","volume":"104","author":"Motta","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2025.106516_bib0016","article-title":"Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy","volume":"10","author":"Schumacher","year":"2022","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"13","key":"10.1016\/j.ejim.2025.106516_bib0017","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"DAPA-HF Investigators and Committees. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: findings From DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejim.2025.106516_bib0018","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12933-023-02027-8","article-title":"Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial","volume":"22","author":"Koshino","year":"2023","journal-title":"Cardiovasc Diabetol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525003942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:00:15Z","timestamp":1762207215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525003942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":18,"alternative-id":["S0953620525003942"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106516","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose cotransporter 2 inhibitors may increase iron availability with beneficial effects on erythropoiesis and cardiovascular mortality in patients with type 2 diabetes mellitus. Author\u2019s Reply","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106516"}}